BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37805620)

  • 1. Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.
    Bittrich M; Hetterich R; Solimando AG; Krebs M; Loda S; Danhof S; Anton S; Zhou X; Kerscher A; Beilhack A; Kortüm KM; Rasche L; Einsele H; Knop S; Hartmann S
    Clin Exp Med; 2023 Dec; 23(8):5215-5226. PubMed ID: 37805620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
    Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
    BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
    Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
    Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
    Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
    J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma identified within the same site of the mandible with medication-related osteonecrosis of jaw: An unusual case report.
    Wu XH; Chen SW
    Medicine (Baltimore); 2023 Jul; 102(29):e34260. PubMed ID: 37478232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 Dec; 30(12):9693-9695. PubMed ID: 36318340
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
    Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
    Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
    Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
    J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
    Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
    Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
    Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
    Tröltzsch M; Tröltzsch M; Pautke C; Otto S
    HNO; 2022 Jul; 70(7):499-507. PubMed ID: 35050392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
    Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
    J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
    Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.